Brief: Hyloris: Enrolment Of First Patient In 4-Arm Clinical Trial Of Alenura

Hyloris Pharmaceuticals SA

22/06/2023 06:04

June 22 (Reuters) - Hyloris Pharmaceuticals SA  HYL.BR :
    * HYLORIS ANNOUNCES ENROLMENT OF FIRST PATIENT IN A 4-ARM
CLINICAL
TRIAL OF ALENURA(TM)
    * POTENTIAL FIRST-LINE TREATMENT FOR INTERSTITIAL
CYSTITIS/BLADDER
PAIN SYNDROME (IC/BPS)
    * GLOBAL OPPORTUNITY WITH A PATIENT POPULATION OF AT LEAST 6
MILLION IN U.S. ALONE
    * PRIMARY ENDPOINT WILL BE TO EVALUATE CHANGE IN SUM OF
BLADDER
PAIN INTENSITY DIFFERENCES FROM BASELINE TO 12 HOURS (SPID-12)
AFTER ADMINISTRATION OF ALENURA
    * HYLORIS WILL BE ELIGIBLE TO RECEIVE A TIERED PERCENTAGE OF
PRODUCT MARGIN GENERATED BY ALENURATM

Source text for Eikon:  ID:nGNEbNwXqN 
Further company coverage:  HYL.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))